Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Reserve your place

Where is pharma's value? October 3rd, 2017. 2pm London, 3pm Paris, 9am New York.

Welcome to a new type of webinar. We invite you to leave your everyday tactical concerns aside for a moment – trust me, you won’t forget them – and take a moment to consider the future of our industry.

As pharma’s customer landscape becomes more complex, our perception of value has changed. Just you wouldn’t be caught dead wearing those flares that were once your most prized possession, it’s no longer enough to focus only on the medicine.

What worked ten years ago does simply not feel right anymore and, increasingly, our customers require more comprehensive solutions.

So what are the disease-specific, technically-specific or customer-specific competencies that will create a new set of assets? How will the medicines we develop require new ways of operating and interacting with our customer?

These questions might feel futuristic, but it is already happening. The recent approval of Novartis’ Kymriah was dependent on a more sophisticated supply chain, and the ability to develop a robust outcomes-based payment model, two things that Novartis had the capacity to execute – but historically, not competencies any of us have considered necessary to have in-house.

  • What will be valued?
    • A long-term view as to the role of the pharmaceutical industry – and how it will be paid for.
  • What competencies will we require in order to deliver this value?
    • How much scientific rigour do commercial teams need? Can you differentiate yourself through competencies in creative pricing and financing contracts?
  • How can we help define future value?
    • What type of value will your company focus on? Can you put a timeline on personalised, preventative and predictive medicine and how you will grow into these areas.

Register now for this exceptional webinar!

Panelists Include:

Thomas Hach

Thomas Hach

Director, Healthcare Systems, Novartis

Andy Jones

Andy Jones

Vice President of Pharmaceutical Innovation, AstraZeneca

Chris Isler

Chris Isler

Director Life Sciences, PA Consulting Group

Stewart Adkins

Stewart Adkins

Director, Pharmaforensic Ltd

Paul Simms

Moderator:
Paul Simms

Chairman, eyeforpharma